CIENCIASMEDICASNEWS

viernes, 9 de octubre de 2026

https://www.medscape.com/viewarticle/ovarian-cancer-mortality-risk-drops-normal-10-years-2026a1000y8d?src= Hello. I'm Dr Maurie Markman, from City of Hope. I would like to discuss a very interesting topic and a very interesting analysis. I would suggest that we need more of these types of analyses. The paper I'm describing is entitled "Long-Term Survival in High-Grade Serous Ovarian Cancer Compared With the General US Population: A 30-Year Landmark Analysis," published in JCO Oncology Advances.

Scalding Drinks Increase Esophageal Cancer Risk (+...)

Oncology Perspective Scalding Drinks Increase Esophageal Cancer Risk Drs Benjamin Levy and Emil Lou discuss new International Journal of Cancer data linking very hot drinks to esophageal cancer risk — and what to tell patients. Medscape Gastroenterology, October 08, 2026 https://www.medscape.com/index/list_13293_0

MHRA Approves New Treatment for Malignant Ascites Dr Sheena Meredith

https://www.medscape.com/viewarticle/mhra-approves-new-treatment-malignant-ascites-2026a10011q2?src= The Medicines and Healthcare products Regulatory Agency (MHRA) has approved catumaxomab (Korjuny, Lindis Biotech) to treat malignant ascites in adults when standard treatment of their cancer is no longer feasible.

Felzartamab Extends PFS in Relapsed Myeloma, but at the Cost of Increased Toxicity October 09, 2026

https://www.medscape.com/viewarticle/felzartamab-extends-pfs-relapsed-myeloma-cost-increased-2026a10011xp?src= Adding felzartamab, a novel anti-CD38 monoclonal antibody, to lenalidomide-dexamethasone significantly extended progression-free survival (PFS) compared with lenalidomide-dexamethasone alone in Chinese patients with relapsed or refractory multiple myeloma, a phase 3 trial found. However, the treatment was associated with substantially greater toxicity, including neutropenia, lymphopenia, and pneumonia.